NHS Framework Agreement - North of England - Tranche B

NHS Framework for the NHS North of England Region, Branded Medicines - Tranche B, Cytokine Modulators and other monoclonal Antibodies, and Fondaparinux Offer reference number: CM/PHR/16/5527 CM/PHR/16/5527/01: NHS Framework for the NHS North Of England Region, Branded Medicines, Tranche B, 1 March 2020 to 28 February 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/16/5527/02: NHS Framework for the NHS North Of England Region, Branded Medicines Annual Tranche, Cytokine Modulators and other monoclonal antibodies, 1 March 2020 to 28 February 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/16/5527/03: NHS Framework agreement for Fondaparinux London, 1 March 2020 to 31 August 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. South of England, 1 March 2020 to 31 August 2020 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Midlands and East, 1 March 2020 to 28 February 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.